Oxford Biomedica PLC OXB Issue of Key US Patent

  Oxford Biomedica PLC (OXB) - Issue of Key US Patent

RNS Number : 7132Q
Oxford Biomedica PLC
09 November 2012




Oxford BioMedica Announces Issue of Key US Patent Relating to RNA Interference
Using Lentiviral Vector Technology



-- Leading intellectual property position further strengthened --



Oxford, UK - 9 November 2012: Oxford BioMedica ("Oxford BioMedica" or "the
Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today
announces that the Carnegie Institution for Science ("Carnegie Institution")
and the University of Massachusetts Medical School ("UMMS") have been granted
a key US patent for the use of RNA interference (RNAi) to inhibit expression
of a target gene in animal cells, including mammalian cells (patent no. US
8,283,329 B2). This patent covers the delivery of RNAi using lentiviral
vectors and, as a result, triggers a modest milestone payment by Oxford
BioMedica for its exclusive rights to this technology.



Lentiviral vectors are used extensively in drug discovery research for
delivery of RNAi to a range of different cell types. In January 2008, Oxford
BioMedica signed a license agreement with Carnegie Institution and UMMS which
granted the Company rights to key RNAi technology invented by Nobel
prize-winning scientists Andrew Z. Fire, PhD, while he was at the Carnegie
Institution, and Craig C. Mello, PhD., a Howard Hughes Medical Institute
Investigator and the Blais University Chair in Molecular Medicine at UMMS. Dr
Fire is now Professor of Pathology and Genetics at the Stanford University
School of Medicine. The rights granted are exclusive for RNAi gene silencing
using lentiviral vector technology for human gene therapy applications,
including the Company's proprietary LentiVector^® platform technology. Under
the terms of the agreement, Oxford BioMedica paid an upfront payment and will
pay milestone payments, subject to the achievement of key events, and
royalties on sales. Further details were not disclosed.



In a separate agreement, originally signed in January 2008, the Carnegie
Institution and the UMMS have agreed to subscribe for a total of 7,910,796
ordinary shares of 1p each at £0.024665 per share. Application will be made
to the United Kingdom Listing Authority (UKLA) for the newly issued ordinary
shares in Oxford BioMedica to be admitted to the Official List of the UKLA and
to the London Stock Exchange plc for admission to trading on its market for
listed securities. The shares are expected to commence trading on 14 November
2012.



John Dawson, Chief Executive Officer of Oxford BioMedica, said:"The
LentiVector^® platform is protected by one of the broadest patent estates in
the field. Delivering RNAi therapeutics using viral vectors is a promising
approach and today's key patent issue further strengthens our world-leading
position in lentiviral vector-based gene therapy strategies."



                                    -Ends-

                                      

For further information, please contact:
Oxford BioMedica plc:                       Tel: +44 (0)1865 783 000

Lara Mott, Head of Corporate Communications
                                           

Media Enquiries:                            Tel: +44 (0)20 7920 2360

Mary Clark/Sarah Macleod/Claire Dickinson

M:Communications





Notes to editors



1. Oxford BioMedica^®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing
innovative gene-based medicines and therapeutic vaccines that aim to improve
the lives of patients with high unmet medical needs. The Company's technology
platform includes a highly efficient LentiVector^® gene delivery system, which
has specific advantages for targeting diseases of the central nervous system
and the eye; and a unique tumour antigen (5T4), which is an ideal target for
anti-cancer therapy. Through in-house and collaborative research, Oxford
BioMedica has a broad pipeline with current partners and licensees including
Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent
BioSolutions, ImaginAb and Immune Design Corp. Further information is
available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.



2. Carnegie Institution for Science

The Carnegie Institution (http://carnegiescience.edu/) has been a pioneering
force in basic scientific research since 1902. It is a private, non-profit
organization with six research departments throughout the U.S. Carnegie
scientists are leaders in plant biology, developmental biology, astronomy,
materials science, global ecology, and Earth and planetary science.



3. University of Massachusetts Medical School

The University of Massachusetts Medical School, one of the fastest growing
academic health centers in the country, has built a reputation as a
world-class research institution, consistently producing noteworthy advances
in clinical and basic research. The Medical School attracts more than $176
million in research funding annually, 80 per cent of which comes from federal
funding sources. UMMS is the academic partner of UMass Memorial Health Care,
the largest health care provider in Central Massachusetts. For more
information, visit www.umassmed.edu.

                     This information is provided by RNS
           The company news service from the London Stock Exchange

END


MSCBKFDNOBDDQDK -0- Nov/09/2012 07:00 GMT